A New Molecule Called YS-ON-001 Attracted Attention for Pancreatic Cancer Treatment

On 26 February 2018, the United States Food and Drug Administration (FDA) was announced to be supporting a different, next-generation immunotherapy agent for pancreatic cancer, the molecule YS-ON-001 .
Pancreatic cancer, although not among the most common cancers, is the 5th leading cause of cancer death. Over the past 50 years, the discovery first of targeted drugs and then immunotherapies has significantly improved survival in many cancers, but these advances have had little impact on pancreatic cancer treatment. The most important reasons are the pancreas’s location and pancreatic cancer’s highly complex tumor microenvironment. Every advance in pancreatic cancer treatment is therefore extremely important.
YS-ON-001 is a biological product developed to regulate the immune system (immunomodulation). It has a broad spectrum of activity on the immune system.
YS-ON-001 is an immunotherapy product with multiple actions altering the tumor microenvironment: triggering special immune substances against tumors (antitumor cytokines), activating natural killer cells, regulating macrophages and suppressing regulatory T cells.
The agent is thought to have potential for use alone or combined with chemotherapy, targeted therapies and other immunotherapies.
YS-ON-001 demonstrated effectiveness in animal studies in tumors of many organs, including breast, lung, liver and pancreas. Animal toxicology studies also showed a favorable safety profile.
Other Topics You May Be Interested In:
- The FOLFIRINOX chemotherapy regimen – pancreatic cancer treatment
- Could new-onset or rapidly worsening diabetes be an early sign of pancreatic cancer?
- Combined treatment for nonmetastatic, inoperable (locally advanced) pancreatic cancer: chemotherapy, radiotherapy, surgery and Nanoknife
- Certain oral bacteria associated with pancreatic cancer risk
Sources
By The ASCO Post
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.